22355-1-AP

antibody from Proteintech Group

Targeting: CXCL9 CMK, crg-10, Humig, MIG, SCYB9

ELISA (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

22355-1-AP

Provider

Proteintech Group

Product name

MIG antibody

Antibody type

Polyclonal

Description

MIG antibody (Cat. #22355-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC,ELISA.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

20ul, 150ul

References

Submitted references

Development and clinical validation of a seven-gene signature based on tumor stem cell-related genes to predict ovarian cancer prognosis.

Wang G, Liu X, You Y, Chen S, Chang X, Yang Q
Journal of ovarian research 2024 Mar 13;17(1):58

---

Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8(+) T cell activity.

Luan X, Lei T, Fang J, Liu X, Fu H, Li Y, Chu W, Jiang P, Tong C, Qi H, Fu Y
Molecular therapy : the journal of the American Society of Gene Therapy 2024 Feb 7;32(2):469-489

---

CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer.

Cheng M, Chen S, Li K, Wang G, Xiong G, Ling R, Zhang C, Zhang Z, Han H, Chen Z, Wang X, Liang Y, Tian G, Zhou R, Zhu Y, Ma J, Liu J, Lin S, Xu H, Chen D, Li Y, Peng L
Nature communications 2024 Apr 1;15(1):2818

---

LRPPRC facilitates tumor progression and immune evasion through upregulation of m(6)A modification of PD-L1 mRNA in hepatocellular carcinoma.

Wang H, Tang A, Cui Y, Gong H, Li H
Frontiers in immunology 2023;14:1144774

---

Identification and Preliminary Clinical Validation of Key Extracellular Proteins as the Potential Biomarkers in Hashimoto's Thyroiditis by Comprehensive Analysis.

Xi Z, Yang T, Huang T, Zhou J, Yang P
Biomedicines 2023 Nov 24;11(12)

---

CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer.

Wu L, Sun S, Qu F, Sun M, Liu X, Sun Q, Cheng L, Zheng Y, Su G
Cancer immunology, immunotherapy : CII 2023 Jun;72(6):1479-1492

---

Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma.

Feng W, Lin A, Sun L, Wei T, Ying H, Zhang J, Luo P, Zhu W
Cancer cell international 2022 May 13;22(1):186

---

A comparison expression analysis of CXCR4, CXCL9 and Caspase-9 in dermal vascular endothelial cells between keloids and normal skin on chemotaxis and apoptosis.

Dong X, Zhang M, Chen Y, Li C, Wang Y, Jin X
Journal of plastic surgery and hand surgery 2022 Apr;56(2):93-102

---

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer.

Liu C, Wang S, Zheng S, Xu F, Cao Z, Feng X, Wang Y, Xue Q, Sun N, He J
Frontiers in immunology 2021;12:782106